Michael S. Rafii
Affiliations: | 2008-2016 | Neuroscience | University of California, San Diego, La Jolla, CA |
| 2016- | Neurology | University of Southern California Keck School of Medicine |
Area:
Neurodegenerative DiseasesGoogle:
"Michael Rafii"Mean distance: 15.77 (cluster 11) | S | N | B | C | P |
Parents
Sign in to add mentor| Carl W. Cotman | research assistant | UC Irvine | ||
| Justin R. Fallon | grad student | 1997-2002 | Brown | |
| (Roles for the proteoglycan biglycan in muscular dystrophy and neuromuscular junction formation.) | ||||
| Leon J. Thal | post-doc | 2006-2008 | UCSD | |
| Paul S. Aisen | research scientist | 2007-2007 | ||
Collaborators
Sign in to add collaborator| James B. Brewer | collaborator | Johns Hopkins | |
| Anders M. Dale | collaborator | UCSD | |
| Robert A Rissman | collaborator |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Rafii MS, Fortea J. (2023) Down Syndrome in a New Era for Alzheimer Disease. Jama |
| Rissman RA, Langford O, Raman R, et al. (2023) Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association |
| Leisher S, Bohorquez A, Gay M, et al. (2023) Amyloid-Lowering Monoclonal Antibodies for the Treatment of Early Alzheimer's Disease. Cns Drugs |
| Sperling RA, Donohue MC, Raman R, et al. (2023) Trial of Solanezumab in Preclinical Alzheimer's Disease. The New England Journal of Medicine |
| Rafii MS, Aisen PS. (2023) Detection and treatment of Alzheimer's disease in its preclinical stage. Nature Aging. 3: 520-531 |
| Baldaranov D, Garcia V, Miller G, et al. (2023) Safety and tolerability of lumbar puncture for the evaluation of Alzheimer's disease. Alzheimer's & Dementia (Amsterdam, Netherlands). 15: e12431 |
| Boerwinkle AH, Gordon BA, Wisch J, et al. (2022) Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study. The Lancet. Neurology. 22: 55-65 |
| Rafii MS, Sperling RA, Donohue MC, et al. (2022) The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association |
| Rafii MS, Sol O, Mobley WC, et al. (2022) Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults With Down Syndrome: A Phase 1b Randomized Clinical Trial. Jama Neurology |
| Aisen PS, Jimenez-Maggiora GA, Rafii MS, et al. (2022) Early-stage Alzheimer disease: getting trial-ready. Nature Reviews. Neurology |